MedPath

BAYER AG

BAYER AG logo
πŸ‡©πŸ‡ͺGermany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Phase 2
Completed
Conditions
Cancer
Melanoma
Interventions
First Posted Date
2005-05-17
Last Posted Date
2015-06-08
Lead Sponsor
Bayer
Target Recruit Count
101
Registration Number
NCT00110994

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Phase 3
Completed
Conditions
Carcinoma, Renal Cell
Interventions
First Posted Date
2005-05-17
Last Posted Date
2014-08-06
Lead Sponsor
Bayer
Target Recruit Count
2567
Registration Number
NCT00111020

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Phase 3
Completed
Conditions
Melanoma
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Carboplatin/Paclitaxel
Drug: Placebo
First Posted Date
2005-05-17
Last Posted Date
2014-10-31
Lead Sponsor
Bayer
Target Recruit Count
270
Registration Number
NCT00111007

Research Study for Patients With Metastatic Renal Cell Carcinoma

Phase 2
Terminated
Conditions
Carcinoma, Renal Cell
Interventions
First Posted Date
2005-05-09
Last Posted Date
2013-10-11
Lead Sponsor
Bayer
Target Recruit Count
1
Registration Number
NCT00110344

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Carcinoma, Hepatocellular
Interventions
First Posted Date
2005-04-22
Last Posted Date
2014-10-31
Lead Sponsor
Bayer
Target Recruit Count
96
Registration Number
NCT00108953

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Phase 3
Completed
Conditions
Carcinoma, Hepatocellular
Interventions
First Posted Date
2005-03-15
Last Posted Date
2014-10-31
Lead Sponsor
Bayer
Target Recruit Count
602
Registration Number
NCT00105443

Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women

Phase 3
Completed
Conditions
Hypertension
Postmenopause
Interventions
Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Drug: Placebo
First Posted Date
2005-01-24
Last Posted Date
2014-12-15
Lead Sponsor
Bayer
Target Recruit Count
750
Registration Number
NCT00102141

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Phase 2
Completed
Conditions
Carcinoma, Non-Small Cell Lung
Cancer
Interventions
First Posted Date
2005-01-11
Last Posted Date
2013-10-30
Lead Sponsor
Bayer
Target Recruit Count
52
Registration Number
NCT00101413

BAY43-9006 - Phase II in Advanced Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Breast Cancer
Interventions
First Posted Date
2005-01-11
Last Posted Date
2013-12-13
Lead Sponsor
Bayer
Target Recruit Count
54
Registration Number
NCT00101400

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Phase 3
Completed
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
First Posted Date
2004-12-16
Last Posted Date
2008-12-19
Lead Sponsor
Bayer
Target Recruit Count
2244
Registration Number
NCT00099502
Β© Copyright 2025. All Rights Reserved by MedPath